Jan 12 (Reuters) - Revvity said on Monday it expects ​its 2025 adjusted profit per ‌share to exceed its forecast of $4.90 ‌to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics ⁠services.

The company's ‌shares were up nearly 6% in extended trading.

Pharmaceutical ‍companies have ramped up drug development in the U.S. amid evolving ​trade policies under President Donald ‌Trump.

Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to ⁠data compiled by ​LSEG.

It also expects ​annual revenue to grow 4% to $2.86 billion, above estimates ‍of $2.84 billion.

The ⁠company will report its fourth-quarter and full year 2025 ⁠results on February 2.

(Reporting by Puyaan ‌Singh in Bengaluru; Editing ‌by Leroy Leo)